Stivarga (Regorafenib) Patent Expiration, LOE Window & CMS Spending

Stivarga (Regorafenib) by Bayer: FDA Orange Book core substance LOE 2032-07-09, 0 AB generics, $120.9M 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBayer
FDA Application & PathwayN203085 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2032-07-09
Last Listed Patent or Exclusivity Date2032-07-09
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$120.9M
2024 Medicare Part D Spend$96.4M
2024 Medicaid Spend$24.5M
Reported Wholesale Price Change (CA SB 17)10 WAC filings (max 22.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.